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Abstract The objectives of this study are to characterize
methamphetamine (MA) usage patterns during pregnancy,
examine whether patterns of MA use are associated with
sociodemographic characteristics and prenatal care, and
test the hypothesis that persistent or increasing MA use
during pregnancy is associated with greater use of other
illicit drugs. The sample consisted of 191 MA-using
mothers who participated in a large-scale multi-site study
of prenatal MA exposure. Patterns of substance use were
assessed by maternal self-report via the Substance Use
Inventory (SUI), which included detailed information
about MA use, including frequency, quantity, and maxi-
mum use during each trimester of pregnancy. The study
demostrated that on average, the prevalence of MA use
decreased over the three trimesters of pregnancy (84.3%
vs. 56.0% vs. 42.4%), and decreased frequency was
observed among users from the ﬁrst trimester to the third
(3.1 vs. 2.4 vs. 1.5 days/week). Closer examination of the
individual patterns revealed that 29.3% of women main-
tained consistently high frequency, 9.4% increased fre-
quency, 25.7% had a stable low/moderate pattern, and
35.6% decreased their frequency of MA over the course
of pregnancy. These four groups did not differ in soci-
odemographic characteristics; women who decreased their
use of MA had signiﬁcantly more prenatal visits com-
pared to the consistently high-use group, but were the
most likely to use alcohol during their pregnancy. In
conclusion, this article elucidated the different patterns of
MA use in this community sample. Approximately, one
third of MA-using mothers could be classiﬁed as consis-
tently high users with a proﬁle of use with the greatest
risk to themselves and potentially to their infants
including high levels of MA use throughout pregnancy
and fewer prenatal care visits. Overall, we found that MA
use declined across pregnancy; however, a substantial
proportion of users had consistently high or increasing
MA use, while those who decreased their MA frequency
had a higher prevalence of polydrug use. Future research
will investigate the association of these patterns with
neonatal outcomes.
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Methamphetamine (MA) use in the U.S. and in other
regions of the world remains a very serious public health
concern [1–7]. The latest data from the National Survey on
Drug Use and Health (NSDUH), an ongoing national
probability survey, estimates that 5.8% of persons ages 12
and older (approximately 14.2 million people) used MA at
least once in their lifetime, including prescription MA. This
may have been underestimated in NSDUH due to its
inclusion within a set of questions about prescription-type
drugs. Speciﬁcally, survey respondents who used meth-
amphetamine might not have reported its use when ques-
tions about it were asked in the context of other questions
about prescription pharmaceuticals.
Other evidence for the magnitude of the MA problem
comes from the Treatment Episode Dataset (TEDS), which
monitors national trends in drug treatment. From these
data, drug treatment admissions where the primary sub-
stance use problem was MA more than doubled between
1995 and 2005, from 3.7 to 9.2% [8, 9]. While Western
regions of the U.S. have the highest prevalence of users,
almost all states have experienced increases in treatment
admissions [10], and non-urban areas are more affected
than major metropolitan areas [5, 11]. The sites included in
the present study (Iowa, California, Hawaii and Oklahoma)
rank in the top ten with respect to the highest rates of MA
treatment admissions [10].
Few studies have attempted to examine the prevalence
of MA use during pregnancy [12]. Further, the epidemi-
ology of the prevalence of methamphetamine use during
pregnancy currently available is limited, varies widely and
is not systematic. According to the 2006–2007 NSDUH, an
ongoing national probability survey, MA use in pregnant
women is reported as 0.1%. The National Pregnancy and
Health Survey (NPHS), based on self-reported use and
urine toxicology, reports less than one percent during
pregnancy. The 2005 TEDS data from client treatment
admissions, estimates a prevalence of one percent. Due to
the methodological limitations in these national surveys,
the true estimated prevalence of MA use in pregnancy is
likely to be underestimated, which could be attributed to
underreporting and surveys not sampling high-risk women
living in rural areas. Estimating the true prevalence of
prenatal MA use can be rather complex because of issues
around sampling methods, accurate self-reported drug use
information and procedures used to detect prenatal drug
use. The available epidemiologic studies on drug use dur-
ing pregnancy are limited in that they report whether or not
use occurred, rather than the amount used [13]. These
estimates vary on the basis of the population sampled,
methods used to collect drug use information and the time
period of data collection [13].
In 2002, we began a study of MA-using mothers and a
matched comparison group to better understand the impact
of prenatal MA exposure and a variety of concomitant
environmental factors on long-term child outcomes. We
reported that 5.2% of pregnant women living in these areas
highly affected by MA use MA during their pregnancy
[14].
The present study follows up these initial ﬁndings by
looking more closely at patterns of MA use during preg-
nancy. To our knowledge, no prior studies have system-
atically described MA use patterns among pregnant
substance-using women. Findings from the NSDUH,
including the prevalence of past 30-day alcohol and other
drug use among 15–44 year old pregnant women by tri-
mester, suggest that women reduce their use of illicit drugs
from the ﬁrst trimester to the last; however, speciﬁc
information is not available on the changing patterns of
MA use during pregnancy [6]. There are two important
reasons why the pattern of MA use during pregnancy is
useful to establish. First, from a scientiﬁc standpoint, it is
important to establish a pattern of use in pregnant MA
users because this information will be crucial to estab-
lishing a dose–response relationship between MA use and
neonatal outcomes. Different patterns of MA use might
very well be associated with different neonatal outcomes.
Short-term neonatal outcome studies from our investigative
team have observed small deﬁcits in infant neurobehavioral
functioning and growth restriction in MA-exposed infants
compared to a matched comparison group [15, 16]. These
studies compared users with non-users but did not relate
neonatal outcomes to quantity and frequency of MA use,
nor consistency of MA use across trimesters. Developing a
typology of MA use during pregnancy can reﬁne the
methodology used in future studies of prenatal MA expo-
sure and infant outcomes.
Second, from a clinical standpoint, it is important to
understand whether sociodemographic subgroups vary with
regard to their MA use pattern. If so, interventions to
reduce use during pregnancy could be tailored to have
maximum impact. Moreover, it would be useful to under-
stand if various MA use patterns during pregnancy are
associated with different proﬁles of concomitant use of
tobacco, alcohol and other drugs. Although some earlier
studies have documented MA use during pregnancy and the
association with polydrug use [17], little information is
available about changing patterns of use during the course
of pregnancy.
The purpose of this study was threefold: (1) to describe
MA use patterns during pregnancy, in terms of quantity and
frequency changes over the course of pregnancy; (2) to
examine whether women with different patterns of MA use
differed with respect to sociodemographic characteristics;
and (3) to test the hypothesis that continued MA use over
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123the course of pregnancy is indicative of a more severe drug
problem, and thus associated with greater use of alcohol,
tobacco and other illicit drugs.
Methods
Overview
The study is part of the Infant Development Environment
and Lifestyle (IDEAL) Study, a multi-site, longitudinal
study of prenatal MA exposure and infant and childhood
outcomes. The IDEAL study involves four clinical sites in
speciﬁc geographic areas of the U.S. known to have MA
problems—Los Angeles, CA; Des Moines, IA; Tulsa, OK;
and Honolulu, HI. At each of the sites, as described below,
MA-using women and their infants were recruited at the
time of delivery and enrolled in this longitudinal study.
Training and re-training of staff occurred at regular inter-
vals to maintain standardization in data collection activi-
ties. The study protocol and consent forms were approved
and reviewed by the Institutional Review Board at each site
and a Certiﬁcate of Conﬁdentiality was obtained from the
National Institute on Drug Abuse to assure the conﬁden-
tiality of information and truthfulness in reporting the
woman’s prenatal drug use. Women were also informed
that should there be any evidence of abuse or neglect, staff
at each site would be mandated to report it. Brieﬂy, at each
of the four clinical sites, all women delivering were
approached for consent to participate in IDEAL. The major
reasons for ineligibility include being non-English
speaking, non-singleton births, and cognitive deﬁcits in the
mother that would preclude informed consent. MA-using
mothers and her matched comparison were identiﬁed by
self-report and/or meconium sample results. An earlier
publication details the original methods used to screen for
eligibility and recruit mothers into the IDEAL study [14].
Subjects who reported use of any opiate, LSD and PCP
were excluded from the study. Among all eligible women
approached for the study, 23% provided informed consent.
Study Participants
There were 204 women classiﬁed as MA exposed. Eight
(1.9%) subjects who denied the use of MA were identiﬁed
as exposed by toxicology only; these women were not
included in this study because the pattern of use could not
be determined; 196 (47.5%) subjects disclosed any
amphetamine use, including ecstasy and other ampheta-
mines. Since the reported unit for ecstasy and other
amphetamines could not be converted to a gram equivalent
(N = 5), we excluded them in this study. Two subjects
reported amphetamine and MA and two subjects reported
ecstasy and MA. In these cases only MA use is described.
To examine polydrug use, we also measured prenatal use of
maternal alcohol, marijuana, and tobacco use in self-
reported MA users (N = 191) (See Fig. 1).
Measures
Each participant was administered the Recruitment Life-
style Interview [18, 19], which covered the following
MA Exposed 
N = 204 
Denied use of MA – Enrolled 
based on toxicology - 
DROPPED 
N = 8 
Disclosed “any MA use” 
(including Ecstasy and 
Amphetamines) 
N = 196 
MA Only 
N = 187 
MA & 
Amphetamine - 
used only MA data 
N = 2 
Ecstasy 
 Only – 
DROPPED 
N = 2 
MA & Ecstasy – 
used only MA data 
 N = 2 
Amphetamine 
Only – 
DROPPED 
N = 3 
191
Fig. 1 MA exposed subjects in
the current study (N = 191)
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123topics: (1) information about the course of her pregnancy
and number of prenatal care visits; (2) demographics,
including education, age, race, marital status, type of
insurance, and socioeconomic status (SES), calculated
using the four-factor Hollingshead index with group 5
indicating low SES [20]; (3) licit and illicit drug use during
pregnancy, assessed by asking ‘‘During your pregnancy,
have you used any of the following drugs?’’ followed by a
series of 14 classes of substances (i.e., methamphetamine,
ecstasy, amphetamines, cocaine, tobacco, alcohol, mari-
juana, hashish, benzodiazepines/tranquilizers, barbiturates/
sedatives, heroin/methadone, other opiates, LSD, and
PCP). Exposure status for all illicit drugs, alcohol,
and tobacco was determined by maternal self-report and
meconium toxicology (relevant for use during the later
stages of pregnancy), except for alcohol which was based
solely on self-report.
For each drug used during pregnancy, a separate series
of questions was asked using the Substance Use Inventory
(SUI), an interview that elicits retrospective reports of
frequency and quantity of drug and alcohol use during four
time periods: 3 months prior to pregnancy and during the
ﬁrst, second, and third trimester of pregnancy. This ques-
tionnaire is based on the Maternal Inventory of Substance
Use (MISU) used in the Maternal Lifestyle Study [21] and
others [22–25]. To assist in recall for each drug used, the
interviewer introduced a calendar with trimesters outlined,
as well as important dates speciﬁc to the postpartum
woman, such as birthdays, anniversaries, holidays, and any
other signiﬁcant life event she was willing to share.
For MA use, the SUI captures age of ﬁrst use; typical
quantity used per day on days of use; average number of
days in 1 week that the average amount was used (every
day, almost every day, 3–4 times week, 1–2 times week,
2–3 times month, once/month, 1–2 times/trimester); cost;
maximum used in 1 day (grams, pills, plates, bowls, other);
and route of administration (sniff/snort, ingest, smoke,
inject). For questions pertaining to quantity, participants
were prompted to report use in grams. If the quantity in
grams was unknown, then ‘‘props’’ were used (e.g., a sugar
packet, in which the contents were equal to 1 g) to help the
participant estimate the number of grams. Five subjects
were unable to report the quantity of MA used during
pregnancy. On some occasions, participants used a variety
of street names to report the speciﬁc quantity of MA used,
and these were converted to grams based on standard and
fairly well-known deﬁnitions (i.e., an ‘‘eight ball’’ is
equivalent to 3.5 g or a ‘‘teener’’ (teena or teenager) is
equivalent to 1/16 of an ounce which equals 1.75 g).
However, less familiar terms, such as ‘‘quarter paper,’’ ‘‘a
line,’’ ‘‘bumps,’’ and ‘‘$20 paper’’ were converted to gram
quantities using information from drug enforcement agen-
cies, drug treatment facilities, and local key informants.
Conversion estimates were acceptable if they could be
veriﬁed with two sources of data.
A variable was constructed for frequency of MA use
based on the number of days per week that the average
quantity was used. Estimates for ‘‘average use’’ were
generated for each trimester separately. Interviewers were
trained to factor in periods of quitting or ‘‘no use’’ into the
estimate of average frequency during the trimester.
Data Reduction
Several summary indices to reﬂect MA use by trimester
were computed, using means and medians including fre-
quency of MA used per week, quantity of MA per occasion
of use, grams/week (quantity multiplied by frequency) and
maximum quantity of MA use. Further, quantity and fre-
quency of tobacco, alcohol and marijuana use were sum-
marized as the number of cigarettes per day, absolute
alcohol per day (ounces), and number of joints per day
(marijuana).
Deﬁning Methamphetamine Use Patterns During
Pregnancy
Because no ‘‘standard’’ deﬁnition exists for MA use pat-
terns during pregnancy, we developed a typology of
changing use patterns during the course of pregnancy using
frequency of use based on studies of prenatal cocaine use
[21, 26–29]. First, the frequency of MA use during each
trimester was categorized as high, moderate, low/no use.
High use was deﬁned as more than 1 day per week, mod-
erate use was deﬁned as one to 3 days per month, and low
use was deﬁned as no use or less than or equal to 1–2 days
in 3 months. The pregnancy was divided into ‘‘the early
period’’ (the ﬁrst trimester) and ‘‘the late period’’, which
spanned the second and third trimesters. The late period
was assigned the highest frequency of either the 2nd or 3rd
trimester. Stability and change of MA use was determined
by comparing the frequency between the early period and
the late period and described as consistently high if there
was high use in both the early and late periods, increasing
use if there was increasing use from the early to the late
period, stable low/moderate if there was low or moderate
use in the early and late periods, decreasing use if there was
a decrease from the early period to the late period.
Statistical Analysis
Version 12.0.1 of SPSS
 for Windows
 (Chicago, IL) was
used for all data analyses. Descriptive statistics (means and
medians) show the quantity and frequency of MA use
during pregnancy in Table 1. The Cochran-Armitage Trend
Test (one sided) was used to test decreasing MA use across
522 Matern Child Health J (2010) 14:519–527
123pregnancy. One-way analysis of variance (ANOVA) with
Tukey-HSD post hoc analyses were used to examine mean
differences between use pattern groups and frequency and
quantity measures (Table 2), prenatal and sociodemo-
graphic characteristics in Table 3 and other substance use
in Table 4. Chi Square analysis was used to test categorical
data in Tables 3 and 4. Results were considered signiﬁcant
at the 0.05 level. Medians were included for informational
purposes only.
Results
Patterns of Methamphetamine Use Characteristics
by Trimester
Table 1 shows the extent to which MA use declined during
the course of pregnancy among the entire sample. Specif-
ically, 84.3% of women used MA in the ﬁrst trimester,
which declined to 56.0% in the second trimester and 42.4%
in the third trimester (Z = 8.39, P\0.001). During the
ﬁrst trimester of pregnancy, almost a quarter of women
used MA every day or almost everyday, which declined to
11.0 and 5.2% in the last two trimesters, respectively.
While the mean number of days used per week and mean
number of grams per week also declined among users,
quantity of MA per use during each trimester was stable for
the ﬁrst two trimesters and then declined in the third tri-
mester. Maximum quantity also showed a decrease from
1.2 g in the ﬁrst, 0.8 g in the second to 0.5 g in the third.
Patterns of Methamphetamine Use During Pregnancy
There was substantial heterogeneity with respect to indi-
vidual MA use patterns among women in the sample. As
shown in Table 2, 29.3% of women were classiﬁed as
consistently high users, a smaller proportion (9.4%)
increased their use (or started their use) in the second tri-
mester or later, another quarter (25.7%) had a stable low/
moderate level of use during all trimesters, and the
remaining 35.6% decreased their use over the course of
pregnancy.
Table 2 compared the use pattern groups to quantity by
frequency measures. Women in the consistently high use
group had signiﬁcantly higher mean frequency of MA use
per week than all of the other groups (all Ps\0.001).
Women who increased their MA use across the pregnancy
had a signiﬁcantly higher mean frequency of MA use
compared to women who had a stable low/moderate fre-
quency (P\0.001). The women in the decreasing group
used a signiﬁcantly greater number of days per week
compared to the stable low/moderate (P\0.001).
Table 1 Frequency and quantity of methamphetamine (MA) use during pregnancy, by trimester (N = 191)
Frequency of MA Use First trimester Second trimester Third trimester
n % n % n %
No use 30 15.7 84 44.0 110 57.6
Some use 161 84.3 107 56.0 81 42.4
1–2 times/pregnancy 28 14.7 23 12.0 34 17.8
Once/month 4 2.1 8 4.2 8 4.2
2–3 times/month 13 6.8 13 6.8 7 3.7
1–2 times/week 29 15.2 20 10.5 13 6.8
3–4 times/week 42 22.0 22 11.5 9 4.7
Almost everyday/daily 45 23.6 21 11.0 10 5.2
Average days/week Mean SD Mean SD Mean SD
3.1 2.5 2.4 2.5 1.5 2.1
Median Range Median Range Median Range
3.5 0.1–7 1.5 0.1–7 0.2 0.1–7
Quantity of MA Mean SD Mean SD Mean SD
Grams/use 0.7 1.3 0.7 1.2 0.4 0.9
Grams/week 3.0 6.3 1.9 5.3 1.4 6.0
Maximum (g/use) 1.2 2.7 0.8 1.4 0.5 1.1
Median Range Median Range Median Range
Grams/use 0.29 0.02–10.5 0.25 0.02–9.0 0.25 0.02–7.0
Grams/week 0.88 0.004–49.0 0.44 0.002–49.0 0.06 0.002–49.0
Maximum (g/use) 0.5 0.02–28.4 0.5 0.02–9.0 0.25 0.02–7.0
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123Compared to woman in the stable low/moderate group,
woman in both the consistently high use group (P = 0.010)
and stable low/moderate group (P = 0.010) used more
grams per week of MA. No other signiﬁcant group dif-
ferences were observed including typical quantity used or
maximum quantity used.
Sociodemographic Characteristics
and Methamphetamine Use Pattern
Table 3 compares the sociodemographic characteristics of
the four MA use pattern groups. There were no signiﬁcant
differences in race/ethnicity, education, SES, insurance
status, marital status, or maternal age. Further there were
no signiﬁcant differences of MA use pattern groups and
site (v
2 = 7.71, df = 9, P = 0.564).
Overall, 38.7% of the sample was White, about one
quarter Hispanic, and a third were Paciﬁc Islander/Asian.
Minority representation mirrored the variations that existed
in the local regions in which the study was conducted.
Thus, race was signiﬁcantly different across sites
(v
2 = 111.18, df = 9, P\0.001). Whites were predomi-
nant in Iowa and Oklahoma (N = 16, 89%, N = 18, 69%,
respectively), Paciﬁc Islander/Asians in Hawaii (N = 51,
70%), and Hispanics in California (N = 36, 49%). There
were no signiﬁcant differences among sites in education,
insurance status, and marital status. On the other hand, the
percentage of low SES was higher in Hawaii (N = 31,
42%) and California (N = 26, 36%) relative to Iowa
(N = 4, 22%) and Oklahoma (N = 2, 8%).
Overall and consistent with our previous report [14],
almost half of the women who used MA during pregnancy
had less than a high school education, a vast majority had
either public or government funded health insurance, and
over half reported not having a partner. The average age of
the sample was 26 years old.
A statistically signiﬁcant association was observed
between the MA use pattern group and prenatal care visits
(P = 0.004). Women who decreased their MA use over the
course of pregnancy had signiﬁcantly more prenatal care
Table 2 Methamphetamine use patterns during pregnancy among 191 methamphetamine-using pregnant women
Methamphetamine use pattern during pregnancy
Consistently high
a (n = 56)
29.3%
Increasing
b (n = 18)
9.4%
Stable low/moderate
c (n = 49)
25.7%
Decreasing
d (n = 68)
35.6%
Mean frequency (days/week) 4.0
e 1.92
e,f 0.16
e,f,g 2.48
e,g
SD 1.85 1.99 0.15 1.70
Median frequency (days/week) 3.5 0.9 0.1 1.8
Range (1.0–7.0) (0.2–7.0) (0.1–0.6) (0.15–7.0)
Mean quantity (g/use) 0.67 0.50 0.44 0.92
SD 1.00 0.73 0.68 1.68
Median quantity (g/use) 0.4 0.2 0.3 0.3
Range (0.08–7.0) (0.04–2.8) (0.03–3.5) (0.02–10.5)
Mean (g/week) 3.46
h 1.65 0.06
h,i 2.87
i
SD 7.00 3.49 0.07 6.11
Median (g/week) 1.4 0.3 0.03 0.8
Range (0.1–49.0) (0.01–13.9) (0.003–0.4) (0.02–36.8)
Mean maximum quantity (g) 0.94 0.56 0.56 1.63
SD 1.33 0.90 0.89 3.91
Median maximum quantity (g) 0.5 0.2 0.3 0.5
Range (0.09–7.0) (0.03–3.7) (0.03–4.0) (0.01–28.4)
a MA use[1 day per week (high) across pregnancy (CH)
b Low–moderate, low to high, moderate to high patterns of MA use (I)
c MA use B1–2 days in 3 months (low), 1–3 days per month (moderate) across pregnancy (SLM)
d High to moderate, high to low, moderate to low patterns of MA use (D)
e CH[I( P\0.001), SLM (P\0.001), D (P\0.001)
f I[SLM (P\0.001)
g SLM\D( P\0.001)
h CH[SLM (P = 0.010)
i SLM\D( P = 0.010)
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123visits (Mean = 13 visits) compared to women who were
consistently high frequency users of MA (Mean = 8 vis-
its). We also observed that on average, women did not
begin prenatal care for this pregnancy until the 2nd tri-
mester and the women who decreased their MA use or who
were stable low/moderate users sought prenatal care
Table 3 Comparison of prenatal and sociodemographic characteristics by methamphetamine use pattern
Methamphetamine use pattern during pregnancy
Consistently high
(n = 56)
Increasing
(n = 18)
Stable low/moderate
(n = 49)
Decreasing
(n = 68)
Total
(n = 191)
n % n % n % n % n %
Race
White, Non-Hispanic 19 33.9 6 33.3 19 38.8 30 44.1 74 38.7
African-American/Black, Non-Hispanic 2 3.6 0 0.0 1 2.0 5 7.4 8 4.2
Hispanic 10 17.9 3 16.7 13 26.5 17 25.0 43 22.5
Paciﬁc Islander/Asian 25 44.6 9 50.0 16 32.7 16 23.5 66 34.6
Education\12 years 29 51.8 7 38.9 25 51.0 26 38.2 87 45.5
Low SES 24 42.9 6 33.3 15 30.6 18 26.9 63 33.2
Public/Govt insurance 49 87.5 17 94.4 45 91.8 61 89.7 172 90.1
Marital status (% no partner) 33 58.9 10 55.6 26 53.1 40 58.8 109 57.1
Mean SD Mean SD Mean SD Mean SD Mean SD
Age (years) 26 5.7 26 5.6 27 6 26 5.5 26.0 5.7
Number of prenatal visits 8
a 5.5 11 8 12 7.5 13
a 7.9 11.3 7.4
Gestational age at 1st prenatal visit (week) 17.8
b 7.3 14.3 9.9 12.5
b 8.1 13.3
b 7.2 14.5 8.0
a CH\D( P = 0.004)
b CH[SLM (P = 0.006), D (P = 0.010)
Table 4 Tobacco, alcohol and other illicit drug use by methamphetamine use pattern during pregnancy
Methamphetamine use pattern during pregnancy
Consistently high (n = 56) Increasing (n = 18) Stable low/moderate (n = 49) Decreasing (n = 68)
n % n % n % n %
Tobacco
Use during pregnancy 46 82.1 16 88.9 42 85.7 53 77.9
Number of cigarettes/day Mean SD Mean SD Mean SD Mean SD
9.70 10.65 6.45 5.83 6.77 7.93 6.14 6.64
Median Range Median Range Median Range Median Range
6 0–47 5 0–20 3 0–33 4 0–23
Alcohol
Use during pregnancy 14
a 25.0 6 33.3 19 38.8 36
a 52.9
Ounces of absolute alcohol/day Mean SD Mean SD Mean SD Mean SD
0.12 0.76 0.12 0.30 0.12 0.40 0.15 0.34
Median Range Median Range Median Range Median Range
0.0 0–5.6 0.0 0–1.2 0.0 0–2.5 0.0 0–1.6
Marijuana
Use during pregnancy 19 33.9 6 33.3 14 28.6 29 42.7
Number of joints/day Mean SD Mean SD Mean SD Mean SD
0.07 0.19 0.06 0.15 0.09 0.29 0.12 0.28
Median Range Median Range Median Range Median Range
0.0 0–1.02 0.00 0–0.48 0.0 0–1.67 0.0 0–1.62
Mean number of drugs used 1.45 (SD = 0.91) 1.61 (SD = 0.92) 1.65 (SD = 0.97) 1.94 (SD = 1.16)
a CH\D( P = 0.016)
Matern Child Health J (2010) 14:519–527 525
123signiﬁcantly earlier than the women who used MA at a
consistently high level (P = 0.010). For reference, the
comparison group (non-MA users) in IDEAL began pre-
natal care at 9 weeks gestation.
Polydrug Use by Patterns of Methamphetamine Use
During Pregnancy
Table 4 compares the MA use pattern groups to use of
other drugs of abuse during pregnancy. The prevalence of
tobacco use was high among all groups (77.9–88.9%), but
did not differ by MA use pattern group. Similarly there
were no group differences in cigarettes per day by MA
pattern group. The prevalence of alcohol use was signiﬁ-
cantly higher in the decreasing group compared to the
consistently high use group (P = 0.016). But the amount of
absolute alcohol per day was not signiﬁcantly different by
MA pattern use group. In addition, there were no signiﬁ-
cant differences of MA pattern use group and prevalence or
joints per day of marijuana. Lastly, there were no signiﬁ-
cant differences of MA pattern use group in the mean
number of drugs used in this sample.
Discussion
This study recruited women from areas in the U.S. with rel-
atively severe problems with MA and described patterns of
MA useduringpregnancy.On average, in thissample of 191
MA-using pregnant women, MA use declined from the ﬁrst
trimester of pregnancy through the last trimester. Impor-
tantly, 42.4% were still using in the third trimester [15, 21].
Whilebynomeansdeﬁnitive,thefourusepatternsdeveloped
inthisstudycouldserveasastartingpointforfutureresearch
investigating the relationship between quantity, frequency
and persistence of MA use and possible long-term neonatal
outcomes associated with prenatal MA exposure.
Looking more closely at individual patterns of MA use,
it was observed that a little more than one-third of women
decreased their use, while about 10% increased their use,
and the remainder (55.0%) did not change their use sig-
niﬁcantly over the course of their pregnancy. Shankaran
et al. [21] observed a similar pattern for use of cocaine
during pregnancy, with the two most frequent patterns of
use characterized as consistently high and decreasing.
Sociodemographic characteristics did not differ signiﬁ-
cantly among the four MA use pattern groups. Future
research should aim to identify factors other than age, race/
ethnicity and socioeconomic status that underlie differ-
ences in MA use patterns. It is quite possible that use
patterns could be related to psychiatric comorbidity [30],
partner conﬂict or abuse, availability of social support, and/
or utilization of treatment services. We did observe that
women who decreased their use of MA over the course of
pregnancy had a greater number of prenatal care visits,
suggesting that prenatal care might have an impact on
reducing MA use, or a less optimistic interpretation, is that
women who decrease their MA use are simply more likely
to visit prenatal care providers.
Contrary to our hypothesis, women who decreased their
MA use were more likely to use alcohol than women who
were consistently high users of MA throughout pregnancy.
This ﬁnding is difﬁcult to interpret, but we can speculate
that one reason for it is that the women might think alcohol
is less harmful than MA. While all women should be
advised to eliminate or at least decrease their MA use
during pregnancy, clinicians should remain vigilant
regarding concomitant or increased alcohol use. Another
explanation for the ﬁnding is that reducing MA use triggers
withdrawal symptoms that could lead to self-medication
with alcohol. If conﬁrmed, this is a potentially serious and
compensatory correlate of decreasing MA use during
pregnancy, given the known adverse neonatal effects of
alcohol. More intervention including retention in treatment
may be needed to support decreasing or quitting MA.
The present study has many strengths and noteworthy
methodological advantages. It is the ﬁrst of its kind to
explore patterns of MA use during pregnancy, it has a
relatively large sample size, it uses structured interviews
administered by trained research personnel, it uses a
detailed questionnaire to obtain substance use history
during each trimester for individual drugs, the levels of use
for each drug. In addition, a study such as this opens the
door for new investigations into how much MA is used by
pregnant women and the patterns of their use.
Nevertheless, the study has some potential limitations.
First, selection bias may be an issue because a substantial
proportion of women declined to participate at an early
stage in the study and therefore, the ﬁndings may not be
generalizable to all MA-using pregnant women. It is pos-
sible that, on average, women who refused to participate
would be more likely to have more severe MA problems.
Another potential limitation of the study is that women
may not have been able to recall the timing and amount of
MA use during their pregnancy; however other research
supports the use of the calendar method to overcome recall
bias [23]. In addition, Jacobson and colleagues [23] dem-
onstrate that the correlation between antenatal and retro-
spective reports of cocaine use during pregnancy was
higher than any of the other drugs used during pregnancy.
More information is critically needed about the effects of
not only maternal drug use, but also the effects of other
adverse life circumstances that often occur in tandem with
illicit drugs on long-term development of children, family
functioning and quality of life. This study underscores the
fact that clinicians who care for pregnant women should be
526 Matern Child Health J (2010) 14:519–527
123comprehensively assessing patients for maternal drug use,
and in areas affected by MA, allocation of resources should
beplannedforinterventionwithMA-usingpregnantwomen.
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